CABA: Rega marang dodolan Cabaletta Bio Inc.
Cabaletta Bio, Inc. (CABA) develops innovative medicines for autoimmune pathologies, leveraging a scientific alliance with the University of Pennsylvania. The price-to-sales ratio reflects the issuer's valuation dynamics, with the current mark standing at . AI systems and robotic bioscreening are accelerating business growth, while the high cost of clinical validation combined with CAR-T patents create a robust defensive barrier.
Rincian analitis perusahaan Cabaletta Bio, Inc (CABA)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- statistik kawajiban utang lan likuiditas:
Utang marang Ekuitas Cabaletta Bio, Inc.|CABA - Utang jangka dawa marang modal|Utang jangka cendhak marang modal Cabaletta Bio Inc|CABA - Utang perusahaan|Rasio utang marang kapitalisasi buku Cabaletta Bio, Inc|CABA - Utang jangka dawa perusahaan|Utang jangka cendhak Cabaletta Bio, Inc.|Rasio likuiditas perantara cabalettabio.com
- data bathi bisnis lan rasio investasi:
CABA - Penghasilan resik|Bathi resik mangsa ngarep Cabaletta Bio, Inc.|CABA - Pangali P/E|Pangali Forward P/E Cabaletta Bio Inc.|CABA - Pangali rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Cabaletta Bio, Inc|CABA - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Cabaletta Bio, Inc.|CABA - Bathi resik saben saham (EPS TTM)|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan cabalettabio.com|CABA - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Cabaletta Bio, Inc.
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:cabalettabio.com CABA
For Cabaletta Bio, Inc. (CABA), whose valuation is based on CAR-T therapy patents and stringent FDA barriers, the P/S ratio reflects the market value of every dollar of revenue. This chart is calculated as the ratio of market capitalization to annual turnover, allowing the investor to assess the degree of overpayment for the asset and determine the current phase of the biotechnology business capitalization cycle.
Perusahaan pesaing
argenx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (BioNTech)|Abivax Pharma (ABVX) - Rega marang dodolan|ADMA Bio - Multiplikator P/S|Protagonist Corp (PTGX) - Kapitalisasi marang pendapatan|IMVT: Multiplikator P/S|kiniksa.com (KNSA) - Multiplikator P/S|GRFS (Grifols) - Multiplikator P/S|Rasio rega marang pendapatan ADPT|Multiplikator P/S CLDX|Multiplikator P/S Aurinia Corp (AUPH)|Rasio rega marang pendapatan BioCryst BCRX|veratx.com - Rasio rega marang pendapatan|Dianthus Therapeutics, Inc. - Multiplikator P/S|Rega marang dodolan Pharvaris NV|ABCL (AbCellera Biologics Inc) - Kapitalisasi marang pendapatan|TRML: Kapitalisasi marang volume dodolan|Kapitalisasi marang pendapatan PGEN|PHAR (pharming.com) - Kapitalisasi marang volume dodolan|Multiplikator P/S NKTR|Multiplikator P/S Upstream Bio, Inc. (UPB)|Zenas Biopharma, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan IMNM|Gossamer Bio, Inc. - Multiplikator P/S|KALV: Rasio rega marang pendapatan|SEPN: Multiplikator P/S|PVLA - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Savara Corp|Rega marang dodolan Rigel Corp RIGL|Kapitalisasi marang pendapatan ANAB (AnaptysBio, Inc.)|ATXS (astriatx.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ENGN (enGene)|Koefisien rega marang pendapatan RAPT Therapeutics Inc. (RAPT)|JBIO - Rasio rega marang pendapatan|ACRS (Aclaris Therapeutics, Inc) - Rasio kapitalisasi marang pendapatan|KYTX: Multiplikator P/S|Kapitalisasi marang pendapatan tizianalifesciences.com|Kapitalisasi marang pendapatan VTYX|Theratechnologies, Inc. (THTX) - Koefisien rega marang pendapatan|Multiplikator P/S AVTX|Kapitalisasi marang pendapatan Eledon Pharmaceuticals, Inc ELDN|Multiplikator P/S AGEN (Agenus)|Multiplikator P/S climbbio.com CLYM|Zura Bio - Multiplikator P/S|ATYR: Rasio rega marang pendapatan|ADAG: Multiplikator P/S|Ikena Oncology (IMA) - Multiplikator P/S|Rasio rega marang pendapatan Shattuck Labs Inc|Equillium Bio - Rasio rega marang dodolan|Multiplikator P/S CNTB|IMUX (immunic-therapeutics.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ATRA (Atara Bio)|Multiplikator P/S InflaRx NV IFRX|XFOR - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ACET (Adicet Bio)|celularity.com (CELU) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan INmune Bio Inc|BRNS (Barinthus Bio) - Multiplikator P/S|Multiplikator P/S Kezar Life Sciences Inc|Kapitalisasi marang pendapatan SABS (SAB Biotherapeutics)|AKTX (akaritx.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ENLV (Enlivex Therapeutics Ltd.)|Koefisien rega marang pendapatan Q32 Bio Inc (QTTB)|GOVX - Rasio rega marang pendapatan|Edesa Biotech Corp (EDSA) - Kapitalisasi marang pendapatan|iBio, Inc. (IBIO) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan Carisma Therapeutics Inc.|Kapitalisasi marang pendapatan XTLB|Multiplikator P/S Bolt Bio|Rasio rega marang pendapatan HCW Biologics Inc. (HCWB)|aptevotherapeutics.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S AIM (AIM ImmunoTech Inc.)|Aditxt Inc. (ADTX) - Rega marang dodolan|GRI Bio - Multiplikator P/S|XORTX Therapeutics Inc (XRTX) - Kapitalisasi marang pendapatan|HIND: Multiplikator P/S|Revelation Biosciences Corp (REVB) - Multiplikator P/S|INDP (Indaptus Therapeutics) - Multiplikator P/S|Rasio rega marang pendapatan SCNI|Multiplikator P/S CALI|Multiplikator P/S affimed.com (AFMD)|Rasio rega marang pendapatan Allakos ALLK|HOOKIPA Pharma, Inc. - Rasio rega marang pendapatan|IGM Bio - Multiplikator P/S|Rega marang dodolan iteostherapeutics.com|OCEA (Ocean Biomedical) - Kapitalisasi marang pendapatan|TCBP: Kapitalisasi marang volume dodolan|Kapitalisasi marang pendapatan THRD
